Stocktoria
Vanda Pharmaceuticals Inc. VNDA
Vanda Pharmaceuticals Inc. (VNDA) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $216.1M at a -102.0% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.413 |
| Retained earnings / assets | -0.807 |
| EBIT / assets | -0.309 |
| Equity / liabilities | 2.023 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| VNDA | Vanda Pharmaceuticals Inc. | 2/9 | 0.13 | — | +8.7% |
| AMRN | AMARIN CORP PLCUK | 5/9 | -2.07 | — | -6.5% |
| IDYA | IDEAYA Biosciences, Inc. | 3/9 | 12.9 | — | — |
| PBYI | PUMA BIOTECHNOLOGY, INC. | 6/9 | -14.13 | 13.3 | -0.9% |
| LFVN | Lifevantage Corp | 6/9 | -0.45 | 8.5 | +14.2% |
| ANAB | ANAPTYSBIO, INC | 5/9 | -0.3 | — | +157% |
| AKBA | Akebia Therapeutics, Inc. | 5/9 | -12.49 | — | +47.5% |
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's commercial portfolio includes Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia; HETLIOZ to treat non-24-hour sleep-wake disorders and nighttime sleep disturbances; PONVORY to treat relapsing forms of multiple sclerosis; and NEREUSTM for preventing vomiting induced by motion. It also develops Fanapt (iloperidone), a long acting injectable (LAI) formulation for the treatment of schizophrenia and hypertension; BysantiTM (milsaperidone), for the acute treatment of manic or mixed episodes associated with bipolar I disorder, and for the treatment of schizophrenia and major depressive disorder; HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, pediatric insomnia, delayed sleep phase disorder, and pediatric Non-24; PONVORY (ponesimod) to treat psoriasis and ulcerative colitis; and NEREUSTM (tradipitant) for prevention of vomiting induced by GLP-1 receptor agonists, as well as treatment of gastroparesis and atopic dermatitis. In addition, the company's products include Imsidolimab, an IL-36R antagonist to treat generalized pustular psoriasis; VTR-297, for the treatment of hematologic malignancies and onychomycosis, and several oncology indications; and VQW-765, small molecule alpha-7 nicotinic acetylcholine receptor partial agonist for the treatment of social/performance anxiety and psychiatric disorders. Further, it develops cystic fibrosis transmembrane conductance regulator activators and inhibitors; and antisense oligonucleotide molecules. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
FAQ
Is VNDA financially healthy?
Vanda Pharmaceuticals Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does VNDA pay a dividend?
No, Vanda Pharmaceuticals Inc. does not currently pay a dividend.
How profitable is VNDA?
In FY2025, Vanda Pharmaceuticals Inc. had a net margin of -102.0% and a return on equity of -67.4%.
Is VNDA overvalued or undervalued?
Vanda Pharmaceuticals Inc. trades at about 129.8× trailing earnings — above its 10-year norm (10-year range 6.0×–90.0×, median 34.1×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for VNDA?
The average Wall-Street price target for Vanda Pharmaceuticals Inc. is $14.12, about 172.2% above the recent price, from 4 analysts.
Is VNDA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Vanda Pharmaceuticals Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.